Phaseline

Targets › GYRAA

GYRAA: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout May 2027.

Open in Phaseline: the race on GYRAA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Boston UniversityLevofloxacin
DNA gyrase inhibitor; Topoisomerase IV inhibitor
GYRAAPhase 2Tuberculosis, Multidrug-ResistantMay 2027

Conditions

Tuberculosis, Multidrug-Resistant (1)

Modalities

small molecule (1)

Companies

Boston University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.